XTX Topco Ltd Acquires New Shares in Mereo BioPharma Group plc (NASDAQ:MREO)

XTX Topco Ltd bought a new position in Mereo BioPharma Group plc (NASDAQ:MREO) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 37,974 shares of the company’s stock, valued at approximately $133,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Sheets Smith Investment Management bought a new position in shares of Mereo BioPharma Group during the 4th quarter valued at $59,000. HealthInvest Partners AB lifted its holdings in Mereo BioPharma Group by 95.0% in the fourth quarter. HealthInvest Partners AB now owns 390,000 shares of the company’s stock valued at $1,373,000 after acquiring an additional 190,000 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in Mereo BioPharma Group in the fourth quarter worth about $37,000. Golden State Equity Partners grew its stake in shares of Mereo BioPharma Group by 247.7% during the 4th quarter. Golden State Equity Partners now owns 22,600 shares of the company’s stock valued at $79,000 after purchasing an additional 16,100 shares during the period. Finally, PFG Investments LLC increased its position in shares of Mereo BioPharma Group by 132.0% during the 4th quarter. PFG Investments LLC now owns 39,433 shares of the company’s stock valued at $138,000 after purchasing an additional 22,433 shares during the last quarter. Institutional investors own 62.83% of the company’s stock.

Mereo BioPharma Group Stock Performance

Shares of MREO stock opened at $2.52 on Wednesday. The stock has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $3.15. The firm has a market capitalization of $400.68 million, a PE ratio of -42.00 and a beta of 0.71. Mereo BioPharma Group plc has a 52-week low of $1.58 and a 52-week high of $5.02.

Mereo BioPharma Group (NASDAQ:MREO) last issued its earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03). On average, sell-side analysts forecast that Mereo BioPharma Group plc will post -0.03 EPS for the current fiscal year.

Analyst Ratings Changes

MREO has been the topic of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. JPMorgan Chase & Co. assumed coverage on Mereo BioPharma Group in a research note on Thursday, March 27th. They issued an “overweight” rating and a $7.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $7.00 target price on shares of Mereo BioPharma Group in a research report on Wednesday, April 9th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.71.

Mereo BioPharma Group Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.